Search Results
Sep 09, 2026, 08:25 ET Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
antitumor activity of [225Ac]Ac-FL-261 in patients with nsNSCLC. Full-Life plans to conduct clinical development in the United States, Australia and other key regions.About [225Ac]Ac-FL-261[225Ac]Ac-FL-261
More news about: Full-Life Technologies
Jan 22, 2026, 10:19 ET ChoiceOne Bank Awards Fresh Coast Alliance with $1 Million Grant In Partnership with the Federal Home Loan Bank of Indianapolis
housing*. FCA also owns and operates ACAC (Alcohol and Chemical Abuse Consultants) which provides licensed, professional therapy for mental health and Substance Use Disorder (SUD). ACAC is one of the few providers in the county that accepts Medicaid to treat SUD. FCA and ACAC will continue to expand quality
More news about: ChoiceOne Bank
Oct 13, 2025, 08:40 ET Full-Life Technologies financiert met US$ 77 miljoen de versnelde ontwikkeling van zijn radiofarmaceutische pijplijn en productiemogelijkheden
Financial Officer van Full-Life. "De financiering zal de voltooiing van de wereldwijde fase I-klinische studie van ons belangrijkste product, [225AC]AC-FL-020 ondersteunen. Daarnaast wordt het geld gebruikt voor het opstarten van verdere klinische studies, het indienen van nieuwe IND-aanvragen wereldwijd
More news about: Full-Life Technologies
Sep 30, 2025, 21:53 ET Full-Life Technologies annonce un financement de 77 millions de dollars américains pour accélérer le développement de son portefeuille de produits radiopharmaceutiques et de ses capacités de fabrication
directrice financière de Full-Life. « Le financement soutiendra l'achèvement de l'essai clinique mondial de phase I de notre principal actif, le [225AC]AC-FL-020, et le lancement d'autres études cliniques, de nouvelles demandes d'autorisation de médicaments expérimentaux dans le monde entier, ainsi que la
More news about: Full-Life Technologies
Sep 29, 2025, 20:00 ET Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities
Officer of Full-Life. "The funding will support completion of the global Phase I clinical trial of our lead asset, [225AC]AC-FL-020, and initiation of further clinical studies, upcoming new IND filings worldwide, as well as the completion of construction of a Good Manufacturing
More news about: Full-Life Technologies